Twisting ribbon of violet, magenta and golden paint on a blue background

Inhaled drug delivery

Our Science

We paint medicines onto the tissues that need them

The challenge

At Paint, we're redefining inhaled drug delivery: getting medicines to the lungs and keeping them there.

Too many pulmonary therapies fail for delivery reasons, not biology. We're closing that gap.

Three textured ribbons of paint in blue, gold and magenta

Our approach

PulmoPaint™

Paint Therapeutics' platform, PulmoPaint™, is a peptide-drug conjugate (PDC) technology designed to improve the performance of inhaled therapies once they reach the lung. Rather than developing new drugs, PulmoPaint™ pairs peptide targeting and linker chemistry with established drugs to address a recurring challenge in respiratory medicine: today's inhaled therapies clear rapidly, distribute systemically, and demand frequent dosing to compensate.

PulmoPaint™ conjugates are designed to:

  • Extend lung residence time

    Keeping active drug where it’s needed for longer.

  • Control release kinetics

    Delivering the payload on a therapeutically useful timeline rather than in an immediate burst.

  • Tune potency through linker design

    Allowing the same platform to be adapted across different payloads and disease targets.

  • Minimize immunogenicity

    Supported by non-immunogenicity data in preclinical mouse models.

Paintbrush sweeping golden paint across a glossy magenta surface

Pipeline

A pulmonary-focused pipeline built on one platform.

Our lead program applies PulmoPaint™ to pulmonary arterial hypertension (PAH) — a rare, progressive, and life-threatening disease where current therapies leave meaningful room for improved performance, tolerability, and dosing convenience.

Development pipeline
Pulmonary disease programs, development stages, and milestones
ProgramModalityIndicationPDC IDIND-enablingStatus
PT-Small moleculeSmall MoleculePulmonary arterial hypertension
Current development stage: PDC ID.
Candidate Nomination2027
PT-BiologicBiologicPulmonary arterial hypertension
Current development stage: PDC ID.
Lead Identification2027
UndisclosedMultipleLung diseases
Current development stage: PDC ID.
No status specified

PT-Small molecule

Modality
Small Molecule
Indication
Pulmonary arterial hypertension
Current development stage: PDC ID.
StatusCandidate Nomination2027

PT-Biologic

Modality
Biologic
Indication
Pulmonary arterial hypertension
Current development stage: PDC ID.
StatusLead Identification2027

Undisclosed

Modality
Multiple
Indication
Lung diseases
Current development stage: PDC ID.
StatusNo status specified
Focused on pulmonary diseases with significant room to improve therapeutic performance.Connect with Paint

Research

Publications

AAPS PharmSci 360 poster: Solving PK Challenges – Inhaled Peptide-Drug Conjugates allow for tunable PK profiles, maximizing efficacy whilst reducing dose and dosing frequency (PDF, opens in a new tab)
AAPS PharmSci 360Poster

Solving PK Challenges – Inhaled Peptide-Drug Conjugates allow for tunable PK profiles, maximizing efficacy whilst reducing dose and dosing frequency

Frank Guarnieri, Mariah Stewart, Dani M. Stoltzfus, Eric Springman

View Poster (opens in a new tab)